0001127602-22-017115.txt : 20220609
0001127602-22-017115.hdr.sgml : 20220609
20220609161404
ACCESSION NUMBER: 0001127602-22-017115
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220607
FILED AS OF DATE: 20220609
DATE AS OF CHANGE: 20220609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Klinger Shannon Thyme
CENTRAL INDEX KEY: 0001866132
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 221006117
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
STREET 2: SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-06-07
0001682852
Moderna, Inc.
MRNA
0001866132
Klinger Shannon Thyme
200 TECHNOLOGY SQUARE
SUITE 300
CAMBRIDGE
MA
02139
1
Chief Legal Officer
Common Stock
2022-06-07
4
M
0
4554
140.00
A
4554
D
Common Stock
2022-06-08
4
S
0
1265
148.1191
D
3289
D
Restricted Stock Units
0
2022-06-07
4
M
0
4554
0
D
2022-06-07
Common Stock
4554
13663
D
Restricted stock units convert into common stock on a one-for-one basis.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive
plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
/s/ Brian Sandstrom, as Attorney-in-Fact
2022-06-09